首页> 美国卫生研究院文献>International Journal of Chronic Obstructive Pulmonary Disease >Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
【2h】

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap

机译:布地奈德/格隆溴铵/福莫特罗富马酸酯三联疗法可改善哮喘-慢性阻塞性肺疾病重叠患者的吸气能力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Asthma-chronic obstructive pulmonary disease overlap (ACO), characterized by airway limitation, is an important condition with high incidence and mortality. Although some guidelines recommend triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β agonists, this treatment approach is based on the extrapolation of data from studies of asthma or chronic obstructive pulmonary disease (COPD) alone.
机译:以气道受限为特征的哮喘-慢性阻塞性肺疾病重叠(ACO)是高发率和高死亡率的重要疾病。尽管一些指南建议采用吸入皮质类固醇/长效毒蕈碱拮抗剂/长效β受体激动剂进行三联疗法,但这种治疗方法仅基于对哮喘或慢性阻塞性肺疾病(COPD)研究数据的推断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号